Search Results - "Voest, E."

Generating and using real-world data: A worthwhile uphill battle by Verkerk, K, Voest, E E

“…The precision oncology paradigm challenges the feasibility and data generalizability of traditional clinical trials. Consequently, an unmet need exists for…”
Get more information

Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers by Scheper, Wouter, Kelderman, Sander, Fanchi, Lorenzo F., Linnemann, Carsten, Bendle, Gavin, de Rooij, Marije A. J., Hirt, Christian, Mezzadra, Riccardo, Slagter, Maarten, Dijkstra, Krijn, Kluin, Roelof J. C., Snaebjornsson, Petur, Milne, Katy, Nelson, Brad H., Zijlmans, Henry, Kenter, Gemma, Voest, Emile E., Haanen, John B. A. G., Schumacher, Ton N.

“…Infiltration of human cancers by T cells is generally interpreted as a sign of immune recognition, and there is a growing effort to reactivate dysfunctional T…”
Get full text

Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine by Dijkstra, Krijn K., Monkhorst, Kim, Schipper, Luuk J., Hartemink, Koen J., Smit, Egbert F., Kaing, Sovann, de Groot, Rosa, Wolkers, Monika C., Clevers, Hans, Cuppen, Edwin, Voest, Emile E.

“…Clinical implementation of tumor organoids for personalized medicine requires that pure tumor organoids can be reliably established. Here, we present our…”
Get full text

Caring for patients with cancer in the COVID-19 era by van de Haar, Joris, Hoes, Louisa R., Coles, Charlotte E., Seamon, Kenneth, Fröhling, Stefan, Jäger, Dirk, Valenza, Franco, de Braud, Filippo, De Petris, Luigi, Bergh, Jonas, Ernberg, Ingemar, Besse, Benjamin, Barlesi, Fabrice, Garralda, Elena, Piris-Giménez, Alejandro, Baumann, Michael, Apolone, Giovanni, Soria, Jean Charles, Tabernero, Josep, Caldas, Carlos, Voest, Emile E.

“…The current COVID-19 pandemic challenges oncologists to profoundly re-organize oncological care in order to dramatically reduce hospital visits and admissions…”
Get full text

Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases by Weeber, Fleur, van de Wetering, Marc, Hoogstraat, Marlous, Dijkstra, Krijn K., Krijgsman, Oscar, Kuilman, Thomas, Gadellaa-van Hooijdonk, Christa G. M., van der Velden, Daphne L., Peeper, Daniel S., Cuppen, Edwin P. J. G., Vries, Robert G., Clevers, Hans, Voest, Emile E.

“…Tumor organoids are 3D cultures of cancer cells. They can be derived from the tumor of each individual patient, thereby providing an attractive ex vivo assay…”
Get full text

Shared and separate functions of polo-like kinases and aurora kinases in cancer by Lens, Susanne M. A, Medema, René H, Voest, Emile E

“…Key Points The polo-like kinases 1–5 (PLK1–5), and aurora kinases, aurora kinase A, aurora kinase B and aurora kinase C have essential roles during cell…”
Get full text

Fixed Dosing of Monoclonal Antibodies in Oncology by Hendrikx, Jeroen J.M.A., Haanen, John B.A.G., Voest, Emile E., Schellens, Jan H.M., Huitema, Alwin D.R., Beijnen, Jos H.

“…Most monoclonal antibodies in oncology are administered in body–size‐based dosing schedules. This is believed to correct for variability in both drug…”
Get full text

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact by van Dessel, Lisanne F., van Riet, Job, Smits, Minke, Zhu, Yanyun, Hamberg, Paul, van der Heijden, Michiel S., Bergman, Andries M., van Oort, Inge M., de Wit, Ronald, Voest, Emile E., Steeghs, Neeltje, Yamaguchi, Takafumi N., Livingstone, Julie, Boutros, Paul C., Martens, John W. M., Sleijfer, Stefan, Cuppen, Edwin, Zwart, Wilbert, van de Werken, Harmen J. G., Mehra, Niven, Lolkema, Martijn P.

“…Metastatic castration-resistant prostate cancer (mCRPC) has a highly complex genomic landscape. With the recent development of novel treatments, accurate…”
Get full text

The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression by Houthuijzen, J M, Daenen, L G M, Roodhart, J M L, Voest, E E

“…It is becoming increasingly clear that the tumour microenvironment has a very important role in tumour progression and drug resistance. Many different cell…”
Get full text

A Phase II Trial of Imatinib Therapy for Metastatic Medullary Thyroid Carcinoma by de Groot, J. W. B., Zonnenberg, B. A., van Ufford-Mannesse, P. Quarles, de Vries, M. M., Links, T. P., Lips, C. J. M., Voest, E. E.

“…Context: Medullary thyroid carcinoma (MTC) metastasizes early in its clinical course. No effective systemic therapy is available. Generally (somatic or…”
Get full text

Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy by Picco, Gabriele, Cattaneo, Chiara M, van Vliet, Esmée J, Crisafulli, Giovanni, Rospo, Giuseppe, Consonni, Sarah, Vieira, Sara F, Rodríguez, Iñigo Sánchez, Cancelliere, Carlotta, Banerjee, Ruby, Schipper, Luuk J, Oddo, Daniele, Dijkstra, Krijn K, Cinatl, Jindrich, Michaelis, Martin, Yang, Fengtang, Di Nicolantonio, Federica, Sartore-Bianchi, Andrea, Siena, Salvatore, Arena, Sabrina, Voest, Emile E, Bardelli, Alberto, Garnett, Mathew J

“…Targeted therapies, chemotherapy, and immunotherapy are used to treat patients with mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H)…”
Get more information

miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo by Holleman, A, Chung, I, Olsen, R R, Kwak, B, Mizokami, A, Saijo, N, Parissenti, A, Duan, Z, Voest, E E, Zetter, B R

“…Cancer cell resistance to paclitaxel continues to be a major clinical problem. In this study, we utilized microRNA (miRNA) arrays to screen for differentially…”
Get full text

Molecular Tumor Boards: current practice and future needs by van der Velden, D.L., van Herpen, C.M.L., van Laarhoven, H.W.M., Smit, E.F., Groen, H.J.M., Willems, S.M., Nederlof, P.M., Langenberg, M.H.G., Cuppen, E., Sleijfer, S., Steeghs, N., Voest, E.E.

“…Due to rapid technical advances, steeply declining sequencing costs, and the ever-increasing number of targeted therapies, it can be expected that extensive…”
Get full text

Symptom Prevalence in Patients with Incurable Cancer: A Systematic Review by Teunissen, Saskia C.C.M., PhD, Wesker, Wendy, MD, Kruitwagen, Cas, MSc, de Haes, Hanneke C.J.M., PhD, Voest, Emile E., MD, PhD, de Graeff, Alexander, PhD

“…Abstract The suffering of patients with incurable cancer is determined to a large degree by the presence and intensity of the symptoms of their disease…”
Get full text

Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens by Cattaneo, Chiara M., Battaglia, Thomas, Urbanus, Jos, Moravec, Ziva, Voogd, Rhianne, de Groot, Rosa, Hartemink, Koen J., Haanen, John B. A. G., Voest, Emile E., Schumacher, Ton N., Scheper, Wouter

“…Cancer neoantigens that arise from tumor mutations are drivers of tumor-specific T cell responses, but identification of T cell-recognized neoantigens in…”
Get full text

Partner independent fusion gene detection by multiplexed CRISPR-Cas9 enrichment and long read nanopore sequencing by Stangl, Christina, de Blank, Sam, Renkens, Ivo, Westera, Liset, Verbeek, Tamara, Valle-Inclan, Jose Espejo, González, Rocio Chamorro, Henssen, Anton G., van Roosmalen, Markus J., Stam, Ronald W., Voest, Emile E., Kloosterman, Wigard P., van Haaften, Gijs, Monroe, Glen R.

“…Fusion genes are hallmarks of various cancer types and important determinants for diagnosis, prognosis and treatment. Fusion gene partner choice and…”
Get full text

Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint by Kleiblova, Petra, Shaltiel, Indra A, Benada, Jan, Ševčík, Jan, Pecháčková, Soňa, Pohlreich, Petr, Voest, Emile E, Dundr, Pavel, Bartek, Jiri, Kleibl, Zdenek, Medema, René H, Macurek, Libor

“…The DNA damage response (DDR) pathway and its core component tumor suppressor p53 block cell cycle progression after genotoxic stress and represent an…”
Get full text

Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer by van Jaarsveld, M T M, Houthuijzen, J M, Voest, E E

“…Over the past decade the importance of lipids for cancer cell metabolism and cancer-related processes such as proliferation, metastasis and chemotherapy…”
Get full text

Intra‐ and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts by Kemper, Kristel, Krijgsman, Oscar, Cornelissen‐Steijger, Paulien, Shahrabi, Aida, Weeber, Fleur, Song, Ji‐Ying, Kuilman, Thomas, Vis, Daniel J, Wessels, Lodewyk F, Voest, Emile E, Schumacher, Ton NM, Blank, Christian U, Adams, David J, Haanen, John B, Peeper, Daniel S

“…The development of targeted inhibitors, like vemurafenib, has greatly improved the clinical outcome of BRAF V600E metastatic melanoma. However, resistance to…”
Get full text

A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer by Kloosterman, Wigard P, Coebergh van den Braak, Robert R J, Pieterse, Mark, van Roosmalen, Markus J, Sieuwerts, Anieta M, Stangl, Christina, Brunekreef, Ronne, Lalmahomed, Zarina S, Ooft, Salo, van Galen, Anne, Smid, Marcel, Lefebvre, Armel, Zwartkruis, Fried, Martens, John W M, Foekens, John A, Biermann, Katharina, Koudijs, Marco J, Ijzermans, Jan N M, Voest, Emile E

“…Genomic rearrangements that give rise to oncogenic gene fusions can offer actionable targets for cancer therapy. Here we present a systematic analysis of…”
Get full text